BiotechTube

Tacrolimus

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma, Bronchial

Conditions

Asthma, Bronchial, Bronchial Asthma

Trial Timeline

— → Jul 1, 2005

NCT ID
NCT00189722

About Tacrolimus

Tacrolimus is a phase 2 stage product being developed by Astellas Pharma for Asthma, Bronchial. The current trial status is completed. This product is registered under clinical trial identifier NCT00189722. Target conditions include Asthma, Bronchial, Bronchial Asthma.

What happened to similar drugs?

20 of 20 similar drugs in Asthma, Bronchial were approved

Approved (20) Terminated (1) Active (0)
✅DuleraMerckApproved
✅Regadenoson + PlaceboAstellas PharmaApproved
✅levalbuterol HCl + albuterol SulfateSumitomo PharmaApproved
✅arformoterol (RR formoterol) + placebo + levalbuterolSumitomo PharmaApproved
✅Racemic albuterol (R+S albuterol) + Levalbuterol (R albuterol)Sumitomo PharmaApproved
✅BenralizumabAstraZenecaApproved
✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT00189761Phase 2Completed
NCT00293930Phase 3Completed
NCT00189787Phase 2Completed
NCT00189722Phase 2Completed
NCT03465969ApprovedCompleted
NCT02555787Pre-clinicalCompleted
NCT02147938Pre-clinicalCompleted
NCT02143479Pre-clinicalCompleted
NCT02159651Pre-clinicalCompleted
NCT02057484Pre-clinicalCompleted
NCT02377609Pre-clinicalTerminated
NCT01745159ApprovedCompleted
NCT01511003ApprovedCompleted
NCT01316133ApprovedTerminated
NCT01410162ApprovedCompleted
NCT02963103ApprovedTerminated
NCT01224041ApprovedCompleted
NCT01224418ApprovedCompleted
NCT00504348Phase 2/3Completed
NCT01410747Pre-clinicalCompleted

Competing Products

20 competing products in Asthma, Bronchial

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
40
DuleraMerckApproved
43
BriquilimabJasper TherapeuticsPhase 1
11
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
35
RoflumilastAstraZenecaPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
35
Regadenoson + PlaceboAstellas PharmaApproved
43
tacrolimusAstellas PharmaPhase 2
35
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
40
rabeprazoleEisaiPhase 3
40
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
35
Placebo + BrodalumabKyowa KirinPhase 2
27
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
35
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
40